Your monthly Monjuvi cost savings if eligible
If you are eligible for the Monjuvi patient assistance program you can receive your medication for free. Our monthly service fee of $49 per medication covers the cost of our services in applying for the program and requesting your ongoing refills on your behalf. If you obtain your Monjuvi through NiceRx, you will only pay $49 a month regardless of the retail price of your medication.
Am I eligible for the Monjuvi patient assistance program?
You could receive your Monjuvi without paying the full retail price if you meet the eligibility criteria for assistance. The eligibility requirements are set by the pharmaceutical companies that are providing assistance programs. At NiceRx, we review each application individually, although the main factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for Monjuvi patient assistance?
We do everything that we can to take the hassle and stress out of applying for patient assistance programs. Simply start by filling in our enrollment application. We will ask for details about your healthcare provider, your insurance, and your household income. This information is required by the pharmaceutical companies you are applying to for assistance. We may also be able to help you access patient assistance for other medications that you have been prescribed, so be sure to tell us about any medications you are taking as well as Monjuvi.
NiceRx will review the information you have provided, and if we determine that you may be eligible for assistance, we will seek to enroll you in the Monjuvi patient assistance program. We will handle the enrollment process for you by working with your healthcare provider and preparing all the required paperwork for your doctor to sign. We will also request your Monjuvi medication refills on your behalf for up to 1 year once you are enrolled in the program.
Is NiceRx a Monjuvi coupons provider?
At NiceRx, we help eligible individuals access the Monjuvi patient assistance program. This means that we are not a Monjuvi coupon, a Monjuvi discount card, or a Monjuvi copay card provider. We do not offer any medication trial offers or free Monjuvi samples.
Can NiceRx help me get Monjuvi if I have insurance?
We may be able to help you if you have insurance, including if your insurance company will not pay for your Monjuvi medication, or you have a high copay or coinsurance responsibility. We may even be able to assist if you do not have insurance. Please fill in our enrollment application to find out more.
How much does Monjuvi cost without insurance?
Monjuvi costs without insurance will vary depending on how much you buy and the retailer you buy it from. As a guide, Monjuvi intravenous powder for injection 200 mg will typically cost around $1,280 for 1 powder for injection. If you obtain your medication through NiceRx, you will pay a flat monthly rate of $49 per medication regardless of its retail price.
How much does Monjuvi cost with insurance?
The copay of Monjuvi will vary in line with the specific terms of your healthcare plan. For further details about what you may need to pay, your insurance provider or pharmacist will be able to calculate the copay costs with your current insurance.
What is Monjuvi?
Monjuvi is an FDA (U.S. Food and Drug Administration) approved medication distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp.
Monjuvi is a CD19-directed cytolytic antibody used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on the overall response rate.
FDA approval of tafasitamab was based on the results of phase 2 L-MIND study, an open-label, multicenter, single-arm clinical trial.
What doses of Monjuvi are available?
Monjuvi is available in injection form, in the following doses: 200 mg of tafasitamab-cxix as a lyophilized powder in a single-dose vial for reconstitution.
Administer premedications prior to starting Monjuvi treatment. The recommended dosage of Monjuvi is 12 mg/kg as an intravenous infusion according to the following dosing schedule:
- Cycle 1: Days 1, 4, 8, 15, and 22 of the 28-day cycle
- Cycles 2 and 3: Days 1, 8, 15, and 22 of each 28-day cycle
- Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle
Administer Monjuvi with lenalidomide for a maximum of 12 cycles and then continue Monjuvi as a monotherapy until disease progression or unacceptable toxicity. See the Full Prescribing Information for instructions on preparation and administration.
Always speak with your healthcare professional about any changes to your dose so they can monitor and evaluate your condition.
Monjuvi active ingredients
The active ingredient in Monjuvi is tafasitamab-cxix.
Monjuvi side effects
The most common adverse reactions of Monjuvi in clinical trials include:
- Peripheral edema
- Respiratory tract infection
- Loss of appetite
Other side effects of Monjuvi can cause more serious side effects. These can include:
- Infusion-related Reactions
- Bacterial, fungal, and viral infections
- Embryo-Fetal Toxicity
Your doctor will assess the benefits of using Monjuvi against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Monjuvi to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Monjuvi drug interactions
Monjuvi can interact with other medications. These include:
- Live vaccines – BCG, measles, mumps, polio, smallpox, rubella
This list is not exhaustive and other prescription drugs may interact with Monjuvi.
You should not use Monjuvi if you:
- Are allergic to the active ingredient tafasitamab-cxix
Talk to your doctor before using Monjuvi if you:
- Are taking any of the medications that could interact with Monjuvi
- Have any signs of infection, or if you have recently had an infection
- Are pregnant or planning to become pregnant – tafasitamab may harm an unborn baby. You are advised to use effective birth control to prevent pregnancy while using this medicine and for at least 3 months after your last dose
- Are breastfeeding or plan to breastfeed – do not breastfeed while receiving Monjuvi, and for at least 3 months after your last dose
Monjuvi is the trademark brand name for tafasitamab-cxix, distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp. A generic version of tafasitamab-cxix is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Monjuvi savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.